Scoring treatment response in patients with relapsing multiple sclerosis

Area of Science:

• Neuroimmunology
• Clinical Neurology
• Biostatistics

Background:

• Multiple sclerosis (MS) management involves assessing patient responses to interferon therapies.
• Magnetic resonance imaging (MRI) and clinical data are crucial for evaluating treatment efficacy.

Purpose of the Study:

• To develop and validate a scoring system for discriminating treatment responses in relapsing-remitting multiple sclerosis (RRMS) patients receiving interferon therapy.
• To optimize a quantitative tool to aid clinicians in predicting patient outcomes.

Main Methods:

• Analysis of two independent RRMS patient datasets (n=373 training, n=222 validation) with 4-year follow-up data.
• Development of a modified scoring system based on early MRI lesions and clinical relapses.
• Evaluation of the score's association with disability progression using survival analysis and Cox regression.

Main Results:

• The developed score (0-3) incorporates new T2 lesions and clinical relapses within the first year of interferon therapy.
• Higher scores correlated with an increased risk of disability progression.
• In the validation set, 3-year progression probabilities were 24% (score 0), 33% (score 1), and 65% (score ≥2).

Conclusions:

• A simple, quantitative scoring tool was developed to predict interferon treatment response in MS.
• This tool can assist clinicians in making informed treatment decisions for RRMS patients.
• The score serves as a complementary measure for assessing treatment efficacy and predicting disease progression.